Alcon says the active ingredient in Triesence, triamcinolone acetonide, has been used for many years to treat retinal disease.
The company said that this new approval brings ophthalmologists a sterile, preservative-free formulation of the compound specifically developed for use in the eye to treat various retinal inflammatory conditions.